China is one of the countries with a high prevalence of hepatitis B virus infection in the higher areas, with more than 300,000 deaths per year due to cirrhosis and liver cancer caused by hepatitis B. Approximately 140,000-161,000 hepatitis B virus-infected pregnancies are delivered in China each year. The ranking of maternal deaths directly or indirectly caused by liver disease is as high as 2-3 in some regions. The incidence of preterm delivery, hemorrhage, neonatal birth defects and other adverse pregnancy outcomes are higher than in the general maternal population. If no interruption measures are taken, 60% of children born to these pregnant women can be infected with hepatitis B virus within two years, and 95% of children born to e antigen-positive mothers are surface antigen positive within one year. 40% -90% of hepatitis B infections occur in the perinatal and childhood periods, and 30% – 90% of these new infections will develop into chronic infections. In China, mother-to-child transmission has become the main route of hepatitis B transmission. The 2010 Chinese guidelines for the prevention and treatment of chronic hepatitis B clearly state that the overall goal of chronic hepatitis B treatment is to maximize long-term inhibition of HBV replication, reduce hepatocyte inflammation necrosis and liver fibrosis, and delay and reduce the occurrence of liver decompensation, cirrhosis, HCC and its complications. Obviously, the primary responsibility of hepatologists is to serve existing hepatitis patients to prolong their life span and improve the quality of survival, while the battlefield of preventing the transmission of hepatitis B migrates to the delivery room, a responsibility that has fallen unavoidably on the shoulders of obstetricians and gynecologists. The main measures of mother-to-child interruption of hepatitis B include the following two points: i. Specific preventive interruption methods: active immunization methods – hepatitis B vaccination, vaccination against hepatitis B is the most effective method to prevent hepatitis B infection. Passive immunization method – hepatitis B immunoglobulin injection for newborns, the protection rate of hepatitis B vaccine alone to block mother-to-child transmission is 87.8%, and the protection rate of combined immunization with high potency hepatitis B immunoglobulin and hepatitis B vaccine to block mother-to-child transmission is 95%-97%. 2010 Chinese guidelines for the prevention and treatment of chronic hepatitis B state: for For newborns of HBsAg-positive mothers, hepatitis B immune globulin (HBIG) should be administered as early as possible within 24 h after birth (preferably within 12 h after birth at a dose of ≥100 IU), along with 10 g of recombinant yeast or 20 mg of Chinese hamster oocyte (CHO) hepatitis B vaccine at different sites, and the second and third doses of hepatitis B vaccine at 1 and 6 months of age, respectively. The effectiveness of blocking mother-to-child transmission is significantly improved. US experts recommend combined immunization with HBIG and hepatitis B vaccine for newborns of HBsAg-positive mothers, and require injection within 12 hours of birth. Second, non-specific preventive measures: pre-birth counseling, assessment, development of a birth plan, supervision and psychological care during pregnancy. Avoid abdominal collision extrusion and shock during pregnancy, protect the integrity of the placental barrier,, and amniocentesis should be avoided as much as possible. Prevent birth canal injuries during labor and delivery, reduce neonatal birth injuries, asphyxia and amniotic fluid aspiration, shorten the delivery time, and minimize the exposure of the newborn to maternal blood. After delivery, newborns are quickly removed from the contaminated environment and can be washed with flowing warm water immediately to remove them from the contaminated environment as soon as possible and reduce the chance of infection. Third, additional blocking measures – nucleoside antiviral therapy: despite immunization and injection of high-valent hepatitis B immunoglobulin, there are still about 5% of newborns infected with hepatitis B. This is the occurrence of new infections through intrauterine transmission, and intrauterine infection becomes the bottleneck of mother-to-child blocking of hepatitis B. High titers of serum HBV-DNA, positive serum HBe -Ag, high titers of HBs-Ag, and placental capillary endothelial cell HBV infection are factors associated with intrauterine transmission. Numerous studies have shown that continuous exposure to high viral load of HBV-DNA is the most important determinant of neonatal infection. Neonatal HBV infection is not only dependent on the host’s immune status and maternal viremia levels, but is also associated with viral heterogeneity. In women with double positive HBsAg and HBeAg and high HBV-DNA levels (HBV-DNA ≥ 1 × 106copies /mL) pregnancy, the intrauterine infection rate of HBV reaches 9.1% to 36.7%, and the intrauterine infection rate is positively correlated with HBV-DNA levels. Anti-disease drugs can effectively inhibit hepatitis virus replication and reduce viral levels. Beijing Ditan Hospital et al. conducted a group study on pregnant women who were double positive for HBsAg and HBeAg and had high copies of HBV DNA (HBV DNA ≥1 × 106copies/mL). Pregnant women in the study group received oral tibivudine 600 mg once/d from 28 weeks of gestation to 1 month postpartum, and the newborns were given hepatitis B vaccine and HBIG for dual active and passive immunization after birth. In the control group, the pregnant women did not take telbivudine, and the newborns were given hepatitis B vaccine and HBIG for dual active and passive immunization after birth. The results showed that, except for the decrease in HBV DNA level in the study group, the rate of HBsAg and HBV-DNA positivity in the infants delivered at 24 h after birth and at 6 and 12 months of age were lower than those in the control group who were given only hepatitis B vaccine and HBIG for active-passive dual immunization at birth, respectively. The blockage rates of vertical transmission of HBV from mother to child in the tebivudine and control groups were 98.3% and 81.7% at 12 months after delivery, respectively. The conclusion shows that if highly effective and safe antiviral drugs are used to inhibit HBV replication in pregnant women with high viral load of hepatitis B, the vertical transmission of HBV from mother to child can be effectively suppressed and the interruption rate improved. Therefore, perinatal maternal antiviral therapy is an effective interruption modality. The introduction of FDA class B nucleoside antivirals, represented by tibivudine, provides a relatively safe option for antiviral therapy for pregnant women. Reducing the viral load, reducing intrauterine transmission, reducing the infant’s exposure to large amounts of HBV during delivery, reducing or eliminating detoxification, reducing or eliminating intrapartum transmission and horizontal transmission, reducing mother-to-child transmission reduces the chance of the offspring being the source of HBV transmission, and reducing the infection rate of susceptible people. Guidelines for the prevention and treatment of chronic hepatitis B state that treatment with lamivudine, telbivudine, or tenofovir may be used depending on the extent of the disease, with adequate information about the risks, weighing the pros and cons, and the patient signing an informed consent form. The rate of birth defects in mothers treated with lamivudine, tenifovir and tenofovir during pregnancy is similar to that of normal pregnant women, as confirmed by national and international research data. Thus the application of antiviral drugs, in addition to the treatment of hepatitis B, may be a complementary means of preventing mother-to-child transmission of hepatitis B. There are also a large number of articles on the use of lamivudine for PMTCT during pregnancy, with conclusions similar to the success rate of tibivudine for PMTCT. However, telbivudine is the only FDA-approved nucleoside (acid) analogue for the treatment of chronic hepatitis B that is currently available in China and is classified as pregnancy category B. It has been shown to have a similar effect on the DNA polymerization of HBV. It has a specific inhibitory effect on the DNA polymerase of HBV, but has no effect on the activity of human DNA polymerase and other human viruses. Toxicological studies have shown that it is non-carcinogenic, non-teratogenic, non-mutagenic, and non-mitochondrial toxic, and does not affect the normal development of infants. Therefore, clinical use of tebivudine is recommended for mother-to-child transmission-blocking antiviral therapy. Adefovir, on the other hand, clearly has adverse effects on the fetus, so it is not suitable for use in pregnant women. If the drug is being taken before pregnancy and pregnancy is detected, the drug should be immediately changed to tebivudine. Patients applying interferon antiviral should consider pregnancy after six months of discontinuation of the drug, and if pregnancy occurs during the use of the drug, termination of pregnancy is recommended. Pregnant women with hepatitis B are full of danger and hope during pregnancy and delivery, so the American Annual Meeting of the Liver Diseases (AASLD), European Annual Meeting of the Liver Diseases (EASL), Asia-Pacific Annual Meeting of the Liver Diseases (APASLD) and China’s guidelines for the prevention and treatment of chronic hepatitis B all recommend that appropriate management processes should be established for women of childbearing age with chronic hepatitis B. The combination of hepatitis B vaccine and immunoglobulin should be selected for the prevention of infants born to HBsAg-positive mothers, and last year In 2000, the Chinese Society for Infectious Diseases established the Obstetric Infectious Diseases and Hepatology Group. In 2000, the Chinese Society of Infectious Diseases established the Obstetric Infectious Diseases and Hepatology Group, which started a close collaboration between the fields of infection and obstetrics. Therefore, it is incumbent on obstetricians and gynecologists to reject hepatitis B.